Last reviewed · How we verify

Succitimal — Competitive Intelligence Brief

Succitimal (PHENSUXIMIDE) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: phensuximide. Area: Neuroscience.

marketed phensuximide Voltage-gated T-type calcium channel Neuroscience Small molecule Live · refreshed every 30 min

Target snapshot

Succitimal (PHENSUXIMIDE).

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Succitimal TARGET PHENSUXIMIDE marketed phensuximide Voltage-gated T-type calcium channel 1982-01-01
Celontin METHSUXIMIDE Pfizer marketed Anti-epileptic Agent Voltage-gated T-type calcium channel 1957-01-01
Paradione PARAMETHADIONE marketed paramethadione Voltage-gated T-type calcium channel 1949-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (phensuximide class)

  1. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Succitimal — Competitive Intelligence Brief. https://druglandscape.com/ci/phensuximide. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing